A heavy-hitter catalyst is about to go up to bat for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) with a key FDA decision looming in the foreground, …
In a research report issued today, Canaccord Genuity analyst John Newman maintained a Hold rating on Acelrx Pharmaceuticals (NASDAQ:ACRX) with an $8 price target, …
In a research report issued today, Roth Capital analyst Ed Arce affirmed a Buy rating on AcelRx Pharmaceuticals Inc. (ACRX) and reduced his price target to $16 (from $22), following …
In a research report issued today, Roth Capital analyst Ed Arce affirmed a Buy rating on AcelRx Pharmaceuticals Inc. (ACRX) with a $22 price target, which represents 121% upside to the current share …
